Sarepta Therapeutics (SRPT) Tops Q4 EPS by 29c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Vifor Pharma said to have confirmed the purchase of Sarepta's (SRPT) Priority Review Voucher - Bloomberg
February 25, 2020 12:14 PM ESTVifor Pharma said to have confirmed the purchase of Sarepta's (NASDAQ: SRPT) Priority Review Voucher, as rumored earlier. - Bloomberg
... MoreSarepta Therapeutics (SRPT) May Have Sold Priority Review Voucher to Vifor - RBC
February 25, 2020 11:03 AM ESTRBC Capital analyst Brian Abrahams said there are signs that Sarepta Therapeutics (NASDAQ: SRPT) sold its Priority Review Voucher to Vifor Pharma.
"... we note a notice emerging just this morning from FTC providing clearance for an undisclosed transaction between SRPT and Vifor... More
